A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
Alogliptin is a selective and potent dipeptidyl peptidase-4 inhibitor developed by Takeda for use in patients with type 2 diabetes mellitus.
Cardiovascular outcomes is of special interest in the type 2 diabetes mellitus population, particularly in type 2 diabetes mellitus patients who have cardiovascular disease and are at high risk for major adverse cardiac events, such as those patients who have had recent acute coronary syndrome.
This study has been designed to evaluate the cardiovascular safety of alogliptin versus placebo in addition to Standard of Care in adults with type 2 diabetes mellitus and acute coronary syndrome.
Inclusion Criteria:
Exclusion Criteria:
Torrence, California, United States
Boilingbrook, Illinois, United States
Forsyth, North Carolina, United States
Lakeridge, Virginia, United States
C0rdoba, Argentina
Capital Federal, Argentina
Carlos Paz, C0rdoba, Argentina
Ciudad Aut0noma de Buenos Aires, Argentina
Ciudad de C0rdoba, Argentina
Cordoba - Cordoba, Argentina
Haedo, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Moron, Buenos Aires, Argentina
Rosario - Santa Fe, Argentina
San Juan, San Juan, Argentina
Aracaju, Sergipe, Brazil
Belem - PA, Brazil
Belo Horizonte - MG, Brazil
Belo Horizonte, Minas Gerais, Brazil
Brasilia - DF, Brazil
Campinas, Sao Paulo, Brazil
Curitiba, Parana, Brazil
Fortaleza - CE, Brazil
Fortaleza, Ceara, Brazil
Goiania, Goias, Brazil
Londrina/PR, Brazil
Macei0, Brazil
Marilia, Sao Paulo, Brazil
Passo Fundo, Rio Grande Do Sul, Brazil
Porto Alegre - RS, Brazil
Porto Alegre, Rio Grande Do Sul, Brazil
Recife, Pernambuco, Brazil
Rio de Janeiro - RJ, Brazil
Salvador - BA, Brazil
Salvador, Bahia, Brazil
Sao Jose Do Rio Preto, Sao Paulo, Brazil
Sao Jose Do Rio Preto- SP, Brazil
Sao Jose, Santa Catarina, Brazil
Sao Paulo, Sao Paulo, Brazil
Uberlandia, Minas Gerais, Brazil
Ontario, Ontario, Canada
Greenfield, Quebec, Canada
Ostrava - Vitkovice, Czechia
Monofia, Egypt
H0dmezovasarhely, Hungary
Hyderabad, Andhra Pradesh, India
Aichi-gun, Aichi-ken, Japan
Ohkawa-city, Fukuoka, Japan
Sagamihara-shi, Kanagawa, Japan
Uji-shi, Kyoto, Japan
Shimajiri-gun, Okinawa, Japan
Yao-shi, Osaka, Japan
Suntou-gun, Shizuoka, Japan
Iwakuni-shi, Yamaguchi, Japan
Dasman, Kuwait
Acapulco, Guerrero, Mexico
Chihuhua, Chihuhua, Mexico
Ciudad Obregon, Sonora, Mexico
Cuernavaca, Morelos, Mexico
Guadalajara, Jalisco, Mexico
Merida, Yucatan, Mexico
Mexicali, Baja California, Mexico
Mexico City, Mexico, Mexico
Monclova, Coahuila, Mexico
Monterrey, Nuevo Leon, Mexico
Morelia, Michoacan, Mexico
Saltillo, Coahuila, Mexico
San Luis Potosi.SLP, Mexico
Xalapa, Veracruz, Mexico
La Victoria, Lima, Peru
Lima San Isidro, Peru
Miraflores, Lima, Peru
San Isidro, Lima, Peru
San Miguel, Lima, Peru
Trujillo, La Libertad, Peru
Halo Rey, PR, Puerto Rico
Kosice - Saca, Slovakia
Tygerberg, Western Cape, South Africa
Kangwon-do, South Korea
Taipei County, Taiwan
Amphure Muang, Thailand
Bangkojk, Thailand
Muang, Thailand
Pathumwan, Thailand
Patumthani, Thailand
Ankara, Balgat, Turkey (Türkiye)
West Midlands, United Kingdom